Back

Biolimus A9 DEB for the Treatment of In-Stent Restenosis. 1-year outcomes of the REFORM trial.

1 September 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Improving techniques and devices for better outcomes in percutaneous coronary interventions Devices ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Rory Durand

Mater Private Hospital, Dublin (Ireland)

7 More presentations in this session

Presentation thumbnail
A retrospective study on real world, 2-stent left main bifurcation PCI using DK crush technique with IVUS guidance - a single center experience
Doctor K. Kaniappan (Kuala Lumpur, MY)
Abstract Slides Video
Presentation thumbnail
OSDOKINA crush technique for the management of side branch ostial lesion ISTANBOL study
Associate Professor I. Donmez (Bolu, TR)
Abstract Slides Video
Presentation thumbnail
Side branch interventions late after MFM implantation
Doctor P. Polomski (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
Safety and feasibility of drug eluting and perfusion therapy for left main disease: JDEPTH-LM pilot study
Doctor T. Warisawa (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Does initial use of large versus small burr size in left main stem bifurcation impact clinical and procedural outcomes?
Doctor A. Alatta (Newcastle-Upon-Tyne, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Improving techniques and devices for better outcomes in percutaneous coronary interventions

The Event

Event poster

ESC Congress 2024

1 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Session
Late-breaking science on acute coronary syndromes
thumbnail
Congress Presentation
Comparative outcomes of drug-coated balloon angioplasty versus second-generation drug-eluting stent for in-stent restenosis: a real-world data analysis
thumbnail
Congress Presentation
REC-CAGEFREE I - Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of de novo coronary artery lesions: a multicenter, non-inferiority trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources